



News Release

Media Contact: Vincent Lamoureux
514-428-3456

MERCK CELEBRATES 50 YEARS OF SCIENCE FAIRS IN QUEBEC

Montreal, February 2, 2010 – The 2010 *Expo-sciences Bell* mark the 50th year of science fairs in Quebec. As a leader in scientific discovery with the largest private biomedical research facility in Canada, Merck has a long standing history of supporting science education in Quebec and is proud to commemorate this historic landmark.

"By fostering science education in our communities we are ensuring that the researchers of tomorrow will have an opportunity to innovate, inspire and contribute to a growing provincial legacy of scientific innovation and progress," said Carlos Dourado, president of Merck in Canada.

This year's *Expo-sciences Bell* will also mark Merck's 19th consecutive year as a major sponsor of the event. Merck's support will comprise of a number of prizes and bursaries to be awarded at various stages of the *Expo-sciences*. Additionally, Merck also sends researchers from our research facility to the *Expo-sciences* to act as judges and to provide students with an exceptional opportunity to discuss and present scientific concepts.

As part of the company's ongoing commitment to science education, and in addition to Merck's support of major events such as the Bell expo-sciences, the company regularly invites Cegep and University level science students for guided tours of our research facility. Merck has also developed a co-op program for graduate students to provide them with opportunities to work with world-class researchers in an environment that is at the leading edge of technology.

In the last 50 years, scientific discoveries and advancements have significantly improved upon the quality of life of all Canadians. Merck congratulates the Conseil de développement du loisir scientifique for all of its efforts to support the sciences and make this historic moment a reality.

About Merck

Today's Merck is working to help the world be well. Merck is a global health care leader with a diversified portfolio of prescription medicines, vaccines, consumer and animal health products. In Canada, Merck markets over 530 pharmaceutical, consumer and animal health products and is a leader in a broad range of areas such as cardiology, immunology, infectious diseases, respiratory, vaccines, women's health and sun care, and is focused on expanding offerings in other areas, including virology, oncology and diabetes.

Merck is one of the top 25 R&D investors in Canada, with an investment of \$103.5 million in 2008 and has one of the largest biomedical research facilities in Canada with the mandate to discover new therapies for the treatment of infectious diseases. For more information about our operations in Canada visit www.merckfrosst.com or www.schering-plough.ca.

*Merck Frosst Canada Ltd. and Schering-Plough Canada Inc. are integrating their operations to form a new organization called Merck.

Forward Looking Statement

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period, due to, among other things, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck's ability to accurately predict future market conditions; dependence on the effectiveness of Merck's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2008 Annual Report on Form 10-K, Schering-Plough's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2009, the proxy statement filed by Merck on June 25, 2009 and each company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).